| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 21, 2026 | Five years of U.S. real-world evidence reinforce the durable effectiveness and long-term persistence of ViiV Healthcare’s Cabenuva | |
| Oct 21, 2026 | CSL appoints Deborah Waterhouse as CEO & Managing Director | MELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director of CSL from 1 Februar... |
| Oct 6, 2026 | ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia | |
| Aug 26, 2026 | U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children | |
| Aug 21, 2026 | Суд отказал ViiV Healthcare в споре о патенте «Биохимика» на долутегравир | Суд отказал ViiV Healthcare в споре о патенте «Биохимика» на долутегравир
Суд по интеллектуальным правам (СИП) отказал ViiV Healthcare в требовании признать недействительным решение Роспатента по интеллектуальным правам «Биохимика» на спосо... |
| Aug 10, 2026 | Суд отказал «Биохимику» в принудительной лицензии на долутегравир | Суд отказал «Биохимику» в принудительной лицензии на долутегравир
Арбитражный суд Москвы отказал «Биохимику» (входит в ГК «Промомед») в принудительной лицензии на использование патента ViiV Healthcare Company и японской Shionogi, защищающег... |
| Jul 29, 2026 | Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil. Multip... |
| Jul 27, 2026 | Grindr for Equality Commits to Connecting 10M to HIV Prevention by 2028 | Today at the 2026 International AIDS Conference, Grindr for Equality committed to connecting ten million LGBTQ+ people to HIV prevention by 2028, leveraging its platform reach to advance the global effort to end HIV by 2030.
The commitment ... |
| Jun 16, 2026 | Colorado receives FDA permission to import cheaper drugs — including Ozempic — from Canada | Getting your Trinity Audio player ready...
Colorado finally has federal permission to start importing cheaper prescription drugs from Canada, but the state may not have any sellers to work with.
Lawmakers passed a bill in 2019 that directed... |
| Feb 25, 2026 | ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults livin... |
| Feb 25, 2026 | ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase str... |
| Jan 25, 2026 | GSK Bolsters Immunology Pipeline with $2.2B RAPT Acquisition | GSK made a significant strategic acquisition. The pharmaceutical giant purchased US biotech RAPT Therapeutics for $2.2 billion. This deal secures global rights to ozureprubart. Ozureprubart is an experimental, long-acting drug. It targets I... |
| Jan 20, 2026 | GSK to acquire US biotech group for $2.2bn | FTSE 100 giant GSK has reached an agreement to acquire US based biotech group Rapt Therapeutics.
The deal values the company, which develops therapies for treating people with inflammatory and immunologic diseases, at $2.2bn (£1.6bn), and m... |
| Jan 15, 2026 | To knock down health-system hurdles between you and HIV prevention, try these 6 things | Getting your Trinity Audio player ready...
By Zach Dyer, Oona Zenda, KFF Health News
When Matthew Hurley was looking to take PrEP to prevent HIV, the doctor hadn’t heard of the medicine, and when he finally did prescribe PrEP, the bills sen... |
| Dec 22, 2025 | GSK strikes deal to cut drug prices with US government | GSK has struck a voluntary agreement with the US government to lower the cost of prescription medicines and expand access to treatments for millions of Americans.
The move comes as pressure mounts on global drugmakers over pricing, tariffs,... |
| Jul 14, 2025 | Newark Pride Parade 2025 Celebrated 20 Years of LGBTQIA+ Visibility | Newark Pride Float
Newark Pride held its celebratory Pride parade on Sunday, July 13, culminating the week-long festivities that started Monday, July 7. The parade, led by Grand Marshals Gary Paul Wright and Jae Quinlan, headed down Broad S... |
| Dec 4, 2024 | Health | A twice-yearly shot could help end AIDS. But will it get to everyone who needs it? | The drug called lenacapavir is already sold under the brand name Sunlenca to treat HIV infections in the U.S., Canada, Europe and elsewhere. The company plans to seek authorization soon for the drug to be used for HIV prevention.
While ther... |
| Aug 9, 2024 | GSK Group begins building relationships with alumni (retirees) using “Official-Alumni.com” provided by Hackazouk | Hackazouk Co., Ltd.
GSK Group begins building relationships with alumni (retirees) using “Official-Alumni.com” provided by Hackazouk
……
Using “Official-Alumni.com,” a specialized alumni service provided by Hackazouk Co., Ltd. (Headquarters:... |
| Aug 9, 2024 | GSK Group begins building relationships with alumni (retirees) using “Official-Alumni.com” provided by Hackazouk | |
| Jun 21, 2024 | National LGBTQ+ Center Destination Tomorrow to Host Annual Da Bronx Pride Festival on June 22 | The Black, Trans-led organization uplifts the New York LGBTQ+ community alongside partners TD Bank, SoBro, Montefiore Health Systems and more.
BRONX, N.Y., June 21, 2024 /PRNewswire/ -- Destination Tomorrow, the national LGBTQ+ grassroots o... |
| May 13, 2024 | Center for Black Equity Announces ViiV Healthcare as Grand Level Sponsor of DC Black Pride 2024 | Center for Black Equity Announces ViiV Healthcare as Grand-Level Sponsor of DC Black Pride 2024 WASHINGTON, DC, USA, May 13, 2024 /EINPresswire.com/ -- The Center for Black Equity (CBE), organizer of DC Black Pride (DCBP), is thrilled to an... |
| Mar 19, 2024 | Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate | A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis
Clinical trial site at University of the Witwatersrand, Johannesburg, South Africa, is first of up to... |
| Apr 3, 2023 | Digital health news, funding round up in the prior week; April 3, 2023 | SimpleTherapy bought PhysMetrics; Wellvana Health raised $84M; Parsley Health expanded to NY and CA
Top Health News
Mantra Health, a provider of virtual mental health services for college students, partnered with Togetherall, an online comm... |
| Oct 19, 2022 | To learn lessons from pandemics, don’t listen to big pharma | Early in the Covid-19 pandemic, the leaders of wealthy countries pledged to respond with “global solidarity.” But when vaccines to prevent the disease were developed, those same leaders pushed low and middle-income countries to the back of ... |
| Jul 19, 2022 | Stop squandering opportunities to end AIDS: be responsive to the needs of HIV prevention users | Ten years ago this month, the Food and Drug Administration approved a daily pill that was up to 99% effective in preventing infection with HIV, the virus that causes AIDS. Expectations were high that this approach, known as oral pre-exposur... |
| Apr 27, 2022 | ViiV Fitness and ViiV Healthcare Reach Trademark Dispute Agreement | viiiv Fitness Enterprises LLC will be a change in company name only. All of our existing customers will still be fully supported and all warrantees will transfer to the new company.
ORLANDO, Fla. (PRWEB) April 27, 2022
ViiV Healthcare and V... |
| Mar 4, 2022 | ViiV causes an outcry by declining to pursue voluntary licensing for its HIV prevention shot | In a surprise move, ViiV Healthcare has decided not to license its long-acting injectable HIV prevention shot so that generic companies could make and distribute less expensive versions to low- and middle-income countries.
The company, whic... |
| Feb 2, 2022 | GSK announces $1.25 billion settlement between ViiV Healthcare, Gilead | The companies have agreed on a patent license and Gilead will also pay a 3% royalty on future U.S. sales of Biktarvy, GSK said in a statement.
(Reporting by Jahnavi Nidumolu in Bengaluru; Editing by Krishna Chandra Eluri) |
| Feb 2, 2022 | GlaxoSmithKline : GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV's dolutegravir patents and entry into a patent licence agreement | GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi & Co. Limited (Shionogi) as shareholders, has agreed to settle the global p... |
| Feb 2, 2022 | GSK announces $1.25 bln settlement between ViiV Healthcare, Gilead | Feb 1 (Reuters) - GlaxoSmithKline PLC announced a settlement worth $1.25 billion between its ViiV Healthcare and Gilead Sciences Inc on Tuesday in relation to patent violations by Gilead's Biktarvy, a medicine to treat human immunodefi... |
| Feb 1, 2022 | GlaxoSmithKline : ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment | For media and investors only
Issued: London UK
Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpi... |
| Dec 21, 2021 | GlaxoSmithKline : ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention | For media and investors only
Issued: London UK
Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition
Approved in the US for use in adults ... |
| Dec 1, 2021 | Forty Years on From the Start of the HIV Epidemic, New Data Reveals People Living With HIV Face Outdated Attitudes and Ongoing Discrimination | Pervasive stigma and prejudice towards people living with HIV continues to persist, according to a new international survey released today on World AIDS Day. Funded by ViiV Healthcare, the global specialist HIV company majority owned by Gla... |
| Oct 28, 2021 | ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be implemented successfully in a variety of European healthcare settings | Issued: London UK
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive interim data from the CARISEL (Ca... |
| Oct 27, 2021 | Download full results announcement PDF - 1.1MB | Press release
Third quarter 2021
Issued: Wednesday, 27 October 2021, London U.K.
GSK delivers strong Q3 sales of £9.1 billion +5% AER, +10% CER
Total EPS 23.3p -7% AER, +3% CER; Adjusted EPS 36.6p +3% AER, +10% CER 2021 full year EPS guidan... |
| Oct 20, 2021 | Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040 | For media and investors only
Issued: London UK
Report from Economist Impact offers key actions to overcome the barriers that have blocked progress in achieving health equity across HIV, STIs, mental health, and COVID-19
ViiV Healthcare toda... |
| Sep 28, 2021 | SHIONOGI : announces out-licensing agreement with ViiV Healthcare to develop third-generation HIV integrase inhibitor, S-365598. | Press Release
SHIONOGI announces out-licensing agreement with ViiV Healthcare
to develop third-generation HIV integrase inhibitor, S-365598,
with potential for ultra long-acting dosing intervals
S-365598 aims to build on the success of dolu... |
| Mar 23, 2021 | How to support your friends and family living with HIV | (BPT) - Starting conversations about health and wellness with loved ones is not easy. These discussions are often harder when someone is living with a condition or disease that is highly stigmatized, such as HIV.
Thankfully, living with HI... |
| Mar 23, 2021 | How to support your friends and family living with HIV | (BPT) - Starting conversations about health and wellness with loved ones is not easy. These discussions are often harder when someone is living with a condition or disease that is highly stigmatized, such as HIV.
Thankfully, living with HI... |
| Jan 27, 2021 | Finding community-driven solutions for a growing health crisis in the Latinx community | (BPT) - For more than four decades, the fight to end the HIV epidemic has raged on, ushering significant developments and innovations in treatment and care. However, progress has been uneven and fragile, illuminating major disparities in ca... |
| Jan 27, 2021 | Finding community-driven solutions for a growing health crisis in the Latinx community | (BPT) - For more than four decades, the fight to end the HIV epidemic has raged on, ushering significant developments and innovations in treatment and care. However, progress has been uneven and fragile, illuminating major disparities in ca... |
| Jan 27, 2021 | Finding community-driven solutions for a growing health crisis in the Latinx community | (BPT) – For more than four decades, the fight to end the HIV epidemic has raged on, ushering significant developments and innovations in treatment and care. However, progress has been uneven and fragile, illuminating major disparities in ca... |
| Jan 22, 2021 | FDA Approves First Monthly Injections To Treat HIV | A medical vial of vaccine with a syringe arranged in studio against a white background.getty |
| Oct 8, 2020 | ICE Raids Are Stopping Latinx Queer And Trans Men From Getting HIV Care | ICE Arrests Undocumented Immigrants In NYCJohn Moore/Staff/Getty Images |
| Oct 1, 2020 | ViiV Healthcare presents a new podcast about the Power of Being Seen
USA - English
USA - español | |
| Mar 9, 2020 | Inovio files for $50M offering amid Covid-19 vaccine hunt; Zydus Cadila signs on with XOMA on IL-2 deal | → Inovio, the company now building a DNA vaccine against the novel coronavirus, has filed for a $50 million equity offering. Touting its experience bringing a vaccine for MERS — a related virus — into Phase II, Inovio... |
| Oct 31, 2018 | WeGo Health aims to cast patients as sophisticated life science industry collaborators | One such entity that hopes to leverage patients with the largest megaphones — read those with significant social media presence — to helping life science companies in everything from product design to product promotion is WEGO Health. In Se... |
| Oct 29, 2018 | Out to challenge Gilead's daily pills, Viiv scores three-year data on monthly combo; Rigel bags $33M from Asia licensing deal | → On the heels of an NDA submission, Viiv has posted longterm data supporting its theory that another one of its long-acting two-drug combos could work just as well as the daily triplets offered by its big rival Gilead. In a... |
| Aug 15, 2018 | Looking to carve away market share from Gilead, ViiV and J&J score positive PhIII data for a monthly, 2-drug HIV injectable | ViiV Healthcare’s future depends on its ability to carve away market share from the blockbuster combination drugs that Gilead uses to dominate the HIV market. And they took another step toward that future today with a se... |
| Jun 6, 2017 | 2 giant drugmakers are racing to make a breakthrough in treating HIV, and there's $22 billion on the line | NIAID
Scanning electromicrograph of an HIV-infected T cell.
The $22 billion HIV drug market is gearing up for a major shake-up over the next year.
Advertisement
Right now, people living with HIV suppress the virus with a regimen of three or... |
| Feb 14, 2017 | Gilead, GSK, share potential advancements in HIV | Over the years, the recipe for these cocktails has been refined. This week, at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, more potential improvements were on display.
On Monday, ViiV Healthcare, GlaxoSmit... |
| Dec 16, 2013 | Siemens will develop companion diagnostics for Pfizer drugs as part of personalized medicine push | The benefits of companion diagnostic tests are not only to ensure that patients receive a particular drug or treatment that has a higher likelihood of effectiveness. They are also to improve the effectiveness of clinical trials and, potenti... |
| Feb 8, 2012 | Siemens partners with ViiV, Tocagen on new personalized medicine tests | An HIV/AIDS treatment developed by GlaxoSmithKline (NYSE:GSK) is now being studied with Siemens (NYSE:SI) to develop companion diagnostics that doctors can use to select patients appropriate for the treatment.
The partnership with ViiV Heal... |
| Feb 1, 2012 | Generic competitor to GSK AIDS drug Epzicom gets tentative FDA approval | Epzicom is GSK’s top-selling HIV treatment and generated $860 million in 2010 sales, $325 million in the United States. The drug is now a product of ViiV Healthcare, a joint venture formed in 2009 with Pfizer (NYSE:PFE) to develop and marke... |
| Jun 20, 2011 | GSK HIV drug pipeline sees boost as partner Concert steers to clinical trials | The identification of a lead drug for treating HIV could be even bigger news for a GSK HIV program that has taken some hits this year. Teva Pharmaceutical in May received U.S. Food and Drug Administration approval on its generic version of ... |
| May 31, 2011 | GSK’s HIV drug combivir to face generic from Teva | Combivir now falls under the umbrella of ViiV Healthcare, a company formed jointly by GSK and Pfizer (NYSE:PFE) in 2009 to market HIV drugs and develop new HIV treatments. The independent company is based in London with U.S. headquarters in... |
| WeGo Health aims to cast patients as sophisticated life science industry collaborators | The Quantified Self movement has been about self-tracking and patients demanding their data from life science companies, and such empowered patients have contributed tremendously to highlighting the basic inequity in our healthcare system: ... |
| Siemens will develop companion diagnostics for Pfizer drugs as part of personalized medicine push | Pharmaceutical companies are keen to have a stake in the personalized medicine market, viewed as a growing trend in the future of healthcare and a significant source of life science innovation. As part of that trend, Siemens‘ (NYSE: SI) dia... |
| GSK HIV drug pipeline sees boost as partner Concert steers to clinical trials | A strategic alliance GlaxoSmithKline (NYSE:GSK) entered into with partner Concert Pharmaceuticals now has a lead drug candidate – a possible new treatment for HIV.
Concert’s selection of CTP-298 as the lead drug candidate means a $4 million... |
| ViiV Healthcare | “ViiV Healthcare is an independent HIV company, committed to delivering innovative new options for the care and treatment of people living with HIV/AIDS.” |
| We can end the HIV epidemic now (with these five steps) | The first cases were reported in 1981. Two years later, scientists discovered the retrovirus causing the disease. And in November of 1983, the World Health Organization began international surveillance.
Since the HIV epidemic began, more th... |
| GSK’s HIV drug combivir to face generic from Teva | GlaxoSmithKline‘s (NYSE:GSK) HIV treatment combivir will soon face its first competition from a generic drug.
Teva Pharmaceutical Industries (NASDAQ:TEVA) has received U.S. Food and Drug Administration approval on its application to market ... |
| Generic competitor to GSK AIDS drug Epzicom gets tentative FDA approval | Generic competition for GlaxoSmithKline (NYSE:GSK) AIDS drug Epzicom is on its way around the world, if not the United States. Yet.
The U.S. Food and Drug Administration has given tentative approval for a formulation of the drug made by Cip... |
| Gilead, GSK, share potential advancements in HIV | HIV drug regimens are arguably the most famous ‘cocktails’ in medicine, comprising three or four primary drugs and many others that help alleviate side effects and improve patients’ quality of life.
Over the years, the recipe for these cock... |
| Siemens partners with ViiV, Tocagen on new personalized medicine tests | An HIV/AIDS treatment developed by GlaxoSmithKline (NYSE:GSK) is now being studied with Siemens (NYSE:SI) to develop companion diagnostics that doctors can use to select patients appropriate for the treatment.
The partnership with ViiV Heal... |
